78,300 Shares in MiMedx Group, Inc $MDXG Bought by Strs Ohio

Key Points

• Strs Ohio acquired a new stake in MiMedx Group, Inc by purchasing 78,300 shares valued at approximately $595,000, representing about 0.05% of the company.
• Brokerages have recently upgraded MiMedx Group's stock, with Wall Street Zen changing its rating to "strong-buy" and Cantor Fitzgerald raising the price target from $11.00 to $12.00.
• MiMedx Group reported a quarterly earnings per share (EPS) of $0.10, surpassing analysts' expectations, with total quarterly revenue of $98.61 million.

Strs Ohio bought a new stake in MiMedx Group, Inc (NASDAQ:MDXG - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 78,300 shares of the company's stock, valued at approximately $595,000. Strs Ohio owned approximately 0.05% of MiMedx Group at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Virtus Advisers LLC purchased a new position in shares of MiMedx Group in the 1st quarter valued at $40,000. Legato Capital Management LLC acquired a new position in MiMedx Group during the 1st quarter worth $101,000. AQR Capital Management LLC boosted its holdings in shares of MiMedx Group by 42.6% in the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company's stock valued at $109,000 after buying an additional 4,296 shares during the period. Ameriprise Financial Inc. acquired a new position in shares of MiMedx Group in the 4th quarter valued at about $115,000. Finally, Sowell Financial Services LLC acquired a new position in shares of MiMedx Group in the 1st quarter valued at about $115,000. Institutional investors and hedge funds own 79.15% of the company's stock.

MiMedx Group Stock Down 1.3%

Shares of MDXG traded down $0.09 during trading hours on Tuesday, reaching $7.10. The stock had a trading volume of 124,159 shares, compared to its average volume of 669,202. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of 33.91 and a beta of 1.74. The firm has a 50-day simple moving average of $7.01 and a 200 day simple moving average of $6.91. MiMedx Group, Inc has a 12 month low of $5.47 and a 12 month high of $10.14. The company has a current ratio of 4.39, a quick ratio of 3.90 and a debt-to-equity ratio of 0.08.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.04. MiMedx Group had a return on equity of 23.03% and a net margin of 8.84%.The company had revenue of $98.61 million during the quarter, compared to analyst estimates of $90.79 million. Equities research analysts predict that MiMedx Group, Inc will post 0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on MDXG. Cantor Fitzgerald boosted their price target on shares of MiMedx Group from $11.00 to $12.00 and gave the stock an "overweight" rating in a research report on Thursday, July 31st. Wall Street Zen raised shares of MiMedx Group from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 2nd. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $12.00.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.